Interlinked Therapeutics

Interlinked Therapeutics is a biotechnology company focused on accelerating drug discovery through its proprietary ITX machine learning platform. The company utilizes graph-based virtual screening and Bayesian-driven Free Energy Perturbation (FEP) to identify novel therapeutic targets and optimize small molecule leads. Interlinked has successfully applied its technology to identify the Interleukin-23 receptor (IL-23R) and the mitochondrial RNA degradosome complex (SUV3 and PNPase) as novel targets in acute myeloid leukemia (AML). Additionally, the company collaborates with the Open Source Malaria consortium to develop inhibitors for PfATP4. By simulating and ranking billions of hypotheses, Interlinked aims to reduce the risks and costs associated with early-stage drug development. The company is headquartered in Portland, Oregon, and operates primarily in the pre-clinical discovery phase.